Taskus Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Taskus Inc trades at $5.86 (market cap $532.07M), while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| TASK | XBI | |
|---|---|---|
Market Cap | $532.07M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $18.21 | $164.28 |
52-Week Low | $4.57 | $85.16 |
Enterprise Value | $927.77M | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →